The Delicate Balance of Brain Cholesterol: Implications for Developmental & Epileptic Encephalopathies (DEEs)
Released On
January 31, 2024
Expires On
January 31, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Neurology, Pediatrics
Topics
Epilepsy
This activity is provided by The France Foundation.
This activity is supported in part by an independent educational grant from Takeda Pharmaceuticals.
Credit Available
- Physicians - maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses - maximum of 1.0 Nursing Contact Hour
- PAs - AAPA Category 1 CME credit
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the educational needs of adult and pediatric epileptologists, adult and pediatric neurologists, and other interested members of the health care team.
Program Overview
This activity covers the science of brain cholesterol as it relates to developmental epileptic encephalopathies (DEEs), as well as the need for new management approaches.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize the effect of brain cholesterol turnover on neurologic health
- Evaluate the impact of dysregulated cholesterol in the brain and implications for developmental epileptic encephalopathies (DEEs)
- Assess ongoing developments in clinical research related to the management of DEEs
Faculty
Dennis Dlugos, MD, MSCE
Professor of Neurology and Pediatrics
Director, Section of Clinical Neurophysiology and the Epilepsy/Clinical Neurophysiology Fellowship
Children’s Hospital of Philadelphia
Philadelphia, PA
Melissa Barker-Haliski, PhD
Research Associate Professor
Co-Director, Center for Epilepsy Drug Discovery (CEDD)
Department of Pharmacy
University of Washington School of Pharmacy
Seattle, WA
Nicole Hawkins, PhD
Research Associate Professor
Northwestern University
Feinburg School of Medicine Pharmacology
Chicago, IL
Accreditation Statement
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 contact hour.
PAs
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 1/31/2025. PAs should only claim credit commensurate with the extent of their participation. All other healthcare professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
Dennis Dlugos, MD, MSCE
- Contract Research: Encoded, Longboard, Takeda Pharmaceuticals, and The Epilepsy Study Consortium
Melissa Barker-Haliski, PhD
- Non-CE Consulting: Atlas Ventures, Inc., Avcentx, Inc., Stoke Therapeutics, and Trevena, Inc.
- Non-CE Speakers Bureau: Praxis, Inc.
- Contract Research: Janssen, Inc., Jazz Pharmaceuticals, and Neurocrine Biosciences, Inc.
Nicole Hawkins, PhD
- Non-CE Consulting: Takeda Pharmaceuticals
- Contract Research: Neurocrine Biosciences, Inc., Ovid Therapeutics/Takeda Pharmaceuticals, and Praxis Precision Medicine
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit, participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity
- Submit the evaluation form
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
For CME questions please contact: [email protected].